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Abstract
Background: Primary Human Papilloma Virus (HPV) testing is the currently recommended cervical cancer (CxCa) screening
strategy by the Portuguese Society of Gynecology (SPG) clinical consensus. However, primary HPV testing has not yet been
adopted by the Portuguese organized screening programs. This modelling study compares clinical benefits and costs of
replacing the current practice, namely cytology with ASCUS HPV triage, with 2 comparative strategies: 1) HPV (pooled) test
with cytology triage, or 2) HPV test with 16/18 genotyping and cytology triage, in organized CxCa screenings in Portugal.
Methods: A budget impact model compares screening performance, clinical outcomes and budget impact of the 3
screening strategies. A hypothetical cohort of 2,078,039 Portuguese women aged 25–64 years old women is followed for
two screening cycles. Screening intervals are 3 years for cytology and 5 years for the HPV strategies. Model inputs include
epidemiological, test performance and medical cost data. Clinical impacts are assessed with the numbers of CIN2–3 and
CxCa detected. Annual costs, budget impact and cost of detecting one CIN2+ were calculated from a public healthcare
payer’s perspective.
Results: HPV testing with HPV16/18 genotyping and cytology triage (comparator 2) shows the best clinical outcomes
at the same cost as comparator 1 and is the most cost-effective CxCa screening strategy in the Portuguese context.
Compared to screening with cytology, it would reduce annual CxCa incidence from 9.3 to 5.3 per 100,000, and CxCa
mortality from 2.7 to 1.1 per 100,000. Further, it generates substantial cost savings by reducing the annual costs by €9.
16 million (− 24%). The cost of detecting CIN2+ decreases from the current €15,845 to €12,795. On the other hand, HPV
(pooled) test with cytology triage (comparator 1) reduces annual incidence of CxCa to 6.9 per 100,000 and CxCa
mortality to 1.6 per 100,000, with a cost of €13,227 per CIN2+ detected with annual savings of €9.36 million (− 24%).
The savings are mainly caused by increasing the length of routine screening intervals from three to five years.
Conclusion: The results support current clinical recommendations to replace cytology with HPV with 16/18
genotyping with cytology triage as screening algorithm.
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Background
Cervical cancer (CxCa) is one of the most common can-
cers in women, with nearly 500,000 new cases being diag-
nosed each year worldwide [1]. Its prevalence represents
relevant costs for patients, their families and countries.
Insiga et al. [2] reported that 75% of CxCa-diagnosed
women died before sixty and 25% before turning forty.
Researchers also estimated that 29% of them would be
professionally active in the year they died and, based on
their salaries’ projections, represented a revenue loss of
1.3 Billion USD, a figure superior to the direct costs asso-
ciated with CxCa in the US. The introduction of cervical
cytology as a screening method in the mid-twentieth cen-
tury contributed to a decrease in the rate of CxCa, but its
low sensitivity for CIN2+ requires a frequent repetition of
the secreening process [3]. As a result, there is need for
more efficient and cost-effective screening methods [4].
Therefore, actual knowledge lead to the definition of new
strategies of prevention and practice management that in-
clude Human Papillomavirus (HPV) testing and prophy-
lactic vaccination. Portugal started the first organized
cervical cancer screening program in the Centre Region in
the late 90’s, extending it to more than half of the country
nowadays. The HPV quadrivalent vaccine was introduced
in the national vaccination program in 2008 extending the
coverage to almost 90% of women. Regarding screening,
the Portuguese Society of Gynaecology consensus docu-
ment considers Pap Cytology with ASCUS HPV triage
every three years as adequate. Nevertheless, also point out
the primary high-risk HPV (hrHPV) testing with cytology
triage every five years as the recommended screening al-
gorithm [5], based on the superior sensitivity of the HPV
assay, validated by prospective clinical trials. Ronco G et
al. (2014) [3] point out that HPV-based screening provides
60–70% greater protection against invasive cervical car-
cinomas when compared to Pap cytology. Following this
recommendation a law decret was published in 2017 con-
firming HPV as the primary screening test with 16/18
genotyping as a triage test for direct colposcopy and Pap
cytology as a triage for other 12 hrHPV types [6], which is
determining a change in the screening algorithm. Despite
this fact, only some of the organized screening programs
implemented the project. In this context, a comparison of
the clinical and budget impact of different screening strat-
egies will help to clarify the health care gains obtained
with the adoption of the new screening algorithm. This is
the first budget impact analysis to date on this subject
evaluating the best scenarios for Portugal.
Methods
Study population
The modelling is carried out on a hypothetical national
cohort of 2,078,039 25–64-year-old Portuguese women fit-
ting the target age groups for cervical cancer screening.
The same cohort was used for all the three screening
strategies under comparison [7], assuming exclusion of in-
eligible patients, such as hysterectomized women. CxCa
screening compliance rate, attendance at re-test and next
routine screening were assumed to be 70.7% [8] and
85.0% [9], respectively.
Compared screening strategies
The compared screening strategies in this evaluation
were based on the Portuguese Society of Gynaecology
consensus on cervical cancer screening [5]. Three pri-
mary CxCa screening strategies are compared. The
current practice: cytology with ASCUS HPV triage every
three years (Fig. 1-a). Women with normal cytology re-
turn to routine screening. Women with LSIL or worse
are referred for colposcopy. ASCUS results are triaged
with pooled HPV test within 6 months. HPV negative
women return to routine screening and HPV-positive
undergo colposcopy.
Comparator strategy 1: HPV (pooled) test with reflex
cytology triage every five years (Fig. 1-b). HPV negative
women return to routine screening. HPV positive results
are triaged with reflex cytology. Women with cytology
results ASCUS or worse are referred for colposcopy.
Normal cytology results are followed up with HPV
re-test in twelve months. Women with HPV-negative
re-test return to routine screening and HPV-positive
re-tests undergo colposcopy.
Comparator strategy 2: HPV test with 16/18 genotyp-
ing with reflex cytology triage every five years (Fig. 1-c).
HPV negative women return to routine screening.
Women with hrHPV genotypes 16/18 are directly re-
ferred for colposcopy. HPV genotypes other than 16/18
(HPV+ 12 types) are triaged with reflex cytology.
Women with cytology results ASCUS or worse are re-
ferred to colposcopy. Normal cytology results are
followed up with HPV re-test in twelve months. Women
with HPV-negative re-test return to routine screening
and HPV-positive re-tests undergo colposcopy.
Model structure
An Excel-based (Microsoft Office 365®) budget impact
model was developed to evaluate screening performance,
clinical outcomes and budget impacts of the CxCa
screening strategies during two routine screening cycles.
The model consists of two main components: a
decision-tree model and a Markov model (Fig. 2). The
decision-tree simulates the performance of the screening
strategies. Women are divided into three groups accord-
ing to their test results; 1) healthy, who return to routine
screening, 2) those who require follow-up testing, and 3)
diagnosed CIN2–3 or CxCa who are treated and exit the
model. The groups 1 and 2 continue to the Markov
model. The Markov model simulates natural history of
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Fig. 1 a The current practice cytology with pooled HPV triage. b Comparator 1 pooled HPV with reflex cytology triage. c Comparator 2 HPV test
with genotyping and reflex cytology triage
Fig. 2 The model structure and patient flow
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HPV infection, CIN and CxCa in one-month cycles.
During each cycle, women can remain on the same
stage, progress to the next, or regress to the previous
stage. The transition probabilities between the health
stages are shown in Table 1 [10–24]. The model does
not differentiate between the stages of CxCa and only in-
cludes the probability of dying from invasive CxCa, not
considering mortality from other causes.
Model inputs
Epidemiology and test performance
The prevalence of HPV (10.5%) and HPV genotypes 16/
18 (2.1%) among 25–64-year-old women are based on
the CLEOPATRE epidemiological study in Portugal [25,
26]. The prevalence of CIN1 (1.4%), CIN2 (0.4%), CIN3
(0.6%) and CxCa (0.048%) are taken from the ATHENA
trial [27]. The US-based trial assessed the performance
of Thinprep® Liquid Based Cytology (Hologic) and the
cobas® HPV test (Roche) in a cohort of 40,900 over
25-year-old women [28] was chosen because it is one of
the largest studies until now to compare the perform-
ance of Pap cytology, HPV test and partial genotyping in
a screening population. Additionally, data from Portugal
on this matte is unavailable. The test performance inputs
of Liquid Based Cytology (LBC) and HPV test (pooled
and 16/18 genotyping) are also based on the ATHENA
trial data (Table 2) [28]. Model inputs were based on the
entire cohort and not stratified by age. Data for the nat-
ural history of cervical cancer was taken from the scien-
tific literature (Table 3). Colposcopy is assumed 100%
sensitive and specific.
Costs
The costs are divided into three main categories; screen-
ing, diagnostic and treatment. Cost inputs are based on
the Portuguese diagnosis-related group (DRG) prices in
2014 and on published data (Table 4) [29–31]. Screening
costs include office visits, primary, triage and re-tests.
Prices for the HPV test (pooled and 16/18 genotyping)
are assumed to be the same as the DRG price of cy-
tology (€27.40) because the current DRG price for the
HPV test was set for a triage scenario and so it is too
high for a primary screening test for CxCa [29]. Diagno-
sis costs relate to diagnostic consultations, colposcopies
and biopsies. Treatment costs include CIN2–3 and CxCa
treatment [30, 31]. The budget impacts are calculated
from the healthcare provider’s perspective and presented
in Euros.
Model outputs
The performance of the screening strategies is assessed
with the percentage of CIN2–3 and CxCa cases detected
and with the number of colposcopies needed to detect
one disease case (CIN2–3 and CxCa). The clinical
impacts, in the screened population, are measured with
an annual incidence of CxCa and annual CxCa mortality.
The costs are presented as average annual costs during
the two routine screening cycles. The annual costs are
used to take into consideration the different routine
screening intervals. Annual budget impacts of the pri-
mary HPV screening strategies are calculated against the
current practice. Further, the costs outputs include the
costs per screened woman and cost of detecting a dis-
ease (CIN2–3 and CxCa).
Sensitivity analysis
A sensitivity analysis was conducted to analyse whether
clinical inputs from different published scientific litera-
ture sources [32–35], other than the primary reference
used, would change the budget impact outputs of the
model. A sensitivity analysis was also conducted to
understand how the variation of the cost of the HPV test
and LBC (half vs double) would affect the budget impact
of the different screening strategies.
Results
Screening performance and clinical outcomes
According to the model results, the current
cytology-based screening strategy detects 51.8% of CxCa
and 51.9% of CIN2–3 cases. Comparator strategy 1:
HPV (pooled) test with reflex cytology triage, increases
the detection of CxCa to 81.0% and of CIN2–3 to 81.4%.
Comparator strategy 2: HPV 16/18 genotyping with re-
flex cytology triage, improves the detection of CxCa to
88.6% and of CIN2–3 cases to 87.3% (Fig. 3). During the
two screening cycles, the screening performances of the
HPV-based comparator strategies 1 and 2 reduce annual
incidence of CxCa in the screened population from
9.3 to 6.9 and 5.3 per 100,000, respectively. Furthermore,
comparators 1 and 2 reduce annual CxCa mortality in
the screened population from cytology-based screening
from 2.7 to 1.6 and 1.1 per 100,000, respectively. This
means avoiding an extra 51 CxCa deaths per year in
comparator 1 and avoiding 85 extra CxCa deaths per
year in comparator 2 for the simulated cohort. The
number of colposcopies needed to detect a disease case
(CIN2–3 and CxCa) also decrease from 10.1 to 8.2 in
comparator 1 and 9.6 in comparator 2 (Table 5).
Budget impact
The average annual costs of the cytology-based strategy
are €34,43 million. Annual costs of comparator 1 are
€29,07 million and comparator 2 represent €29,26 mil-
lion (Fig. 4). Both primary HPV screening strategies ori-
ginate cost-savings. Comparator 1 decreases the total
annual costs in €9,36 million (− 24%) and comparator 2
in €9,16 million (− 24%).
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Figure 4 portrays a breakdown of annual costs of the three
screening strategies. Screening costs are the largest compo-
nent of all the three strategies. Annual screening costs
(screening and triage tests and office visits) of the current
practice and comparators 1 and 2 are €32,79 million, €24,41
million (− 25.6%) and €24,30 million (− 25.9%), respectively.
Overall cost savings result from the reduction of screening
costs. These cost savings are caused by the longer routine
screening interval of the primary HPV screening strategies.
Annual diagnosis costs (follow-up consultations, colposco-
pies and biopsies) of the current practice and comparators 1
and 2 are €1,85 million, €1,22 million (− 34.0%) and €1,53
million (− 17.0%), respectively. In both primary HPV screen-
ing strategies, the declining incidence of CIN2–3 and CxCa
results in lower annual treatment costs. The treatment costs
(CIN2–3 and CxCa combined) decline from €1,75 million to
€1,58 million (− 9.7%) in comparator 1 and to €1,49 million
(− 14.8%) in comparator 2. Average cost per screened
women in the current practice and comparators 1 and 2 are
€18,49, €13,99 and €14,08, respectively. In addition, the cost
of detecting a disease case (CIN2–3 or CxCa) decreases from
€15,845 to €13,227 in comparator 1 and to €12,795 in com-
parator 2.
Sensitivity analysis
The sensitivity analysis shows that the comparator
screening algorithms accuracy varies in a higher level
than relative costs versus the current practice. Compara-
tor 1 (Table 6) and 2 (Table 7) would reduce costs vs
Table 1 Annual transition (progression / regression)
probabilities of the Markov model; Natural history inputs for
HPV infection, CIN, and cervical cancer
Model
input
References
Annual Progressio
Well to hrHPV
infection
4.2% Kulasingam et al. (2011) [10]
Progression from hrHPV (12 types)
to CIN1 8.1% Kulasingam et al. (2011) [10]; Insinga
RP et al. (2007) [11]
to CIN2 0.1% Khan MJ et al. (2005) [12]
to CIN3 0.1%
Progression from hrHPV 16/18
to CIN1 9.9% Insinga RP et al. (2007) [11]; Insinga
RP et al. (2009) [13]
to CIN2 0.6% Khan MJ et al. (2005) [12]
to CIN3 1.5%
Progression from CIN1
to CIN2 3.2% Weighted average: Kataja V et al.
(1989) [14]; Holowaty P et al. (1999)
[15]; Matsumoto K et al. (2006) [16];
Omori M et al. (2007) [17]; Guedes
AC et al. (2010) [18]
to CIN3 0.9%
to CxCa 0.3%
Progression from CIN2
to CIN3 4.2% Weighted average: Kataja V et al.
(1989) [14]; Holowaty P et al. (1999)
[15]; Matsumoto K et al. (2006) [16];
Omori M et al. (2007) [17]; Guedes
AC et al. (2010) [18]
to CxCa 1.8%
CIN3 to CxCa 3.4% Weighted average: Kataja V et al.
(1989) [14]; Holowaty P et al. (1999)
[15]; McCredie et al. (2008) [19]
Annual mortality rate
for CxCa
0.6% SEER data. 5 year survival of 68%
converted to annual mortality
rate [20]
Annual Regression
Regression from hrHPV (12 types)
with normal
cytology to well
58.6% Bulkmans NJ et al. (2007) [21]
with borderline/
mild cytology to
well
45.6%
Regression from hrHPV 16/18
with normal
cytology to well
43.8% Bulkmans NJ et al. (2007) [21]
with borderline/
mild cytology
to well
21.8%
Regression from CIN1
to well 21.2% Weighted average: Kataja V et al.
(1989) [14]; Holowaty P et al. (1999)
[15]; Matsumoto K et al. (2010) [22]to hrHPV 2.4%
Regression from CIN2
to well 9.4% Weighted average: Kataja V et al.
Table 1 Annual transition (progression / regression)
probabilities of the Markov model; Natural history inputs for
HPV infection, CIN, and cervical cancer (Continued)
Model
input
References
(1989) [14]; Meyskens FL Jr. et al.
(1994) [23]; Holowaty P et al. (1999)
[15]; Matsumoto K et al. (2006) [16];
Omori M et al. (2007) [17]; Castle
PE et al. (2009) [24]; Guedes AC et al.
(2010) [18]
to CIN1 9.4%
Regression from CIN3
to well 3.9% Weighted average: Kataja V et al. (1989)
[14]; McCredie et al. (2008) [19]
to CIN1 1.6%
Table 2 Prevalence of HPV, CIN and Cervical Cancer
Prevalence of hrHPV 8.4% Pista et al. (2013) [26]
Prevalence of HPV16 and/or 18 2.4% Pista et al. (2013) [26]
Prevalence of CIN1 1.4% Wright et al. (2012) [27]
Prevalence of CIN2 0.4% Wright et al. (2012) [27]
Prevalence of CIN3 0.6% Wright et al. (2012) [27]
Prevalence of invasive cervical cancer 0.048% Wright et al. (2012) [27]
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usual care if inputs from the POBASCAM and PavDag
studies would be used for modelling instead of the
ATHENA [32,33]. Modelling with an LBC sensitivity of
73.0% for pap cytology sensitivity in this model (highest
pap cytology sensitivity for CIN2+ found in the
ATHENA trial) [34], would improve the clinical per-
formance of usual care, but would not alter the cost dif-
ference towards comparator strategies. On the other
hand, cutting the cost of the HPV test by half (€13,7)
would improve the savings vs usual care to 38.0% for
comparators 1 and 2, while doubling the HPV test cost
(€54,8) would still save 3.0% of the screening budget for
Comparator 1 or 2.
Discussion
Overall, the output of the decision-tree and Markov model
suggest the replacement of the current cytology-based
screening with any of the two primary HPV screening strat-
egies. It improves the detection of CIN2–3 and CxCa, dis-
plays better clinical outcomes and creates substantial
cost-savings for the Portuguese healthcare system. The re-
sults are in line with similar health economic outcome re-
search (HECON) studies [36–39] and support the current
clinical consensus on the move towards molecular screen-
ing for cervical cancer not just in Portugal but also other
European countries. Nevertheless, as this study is based on
a computer-based model cohort, a randomized clinical trial
or real-world studies with randomized samples and appro-
priate methodologies are needed as further research to
generalize these results to the population.
The major goal of cervical cancer screening is to de-
tect its precursor lesions and treat them before they be-
come invasive. According to the findings of the
meta-analysis of 4 European randomized trials (Swedesc-
reen (Sweden) [40], POBASCAM (Netherlands) [41],
ARTISTIC (England) [42] and NTCC (Italy) [43], rein-
forced by the recent findings of the COMPASS
(Australia) [44] and FOCAL (Canada) [45]), HPV-based
screening provides 60–70% greater protection against in-
vasive cervical carcinomas compared with Pap cytology
and that screening intervals may be extended to at least
five years [3]. In the US, the Kaiser Permanente North-
ern California (analysing data from more than 330,000
women) [46] and the ATHENA trial (recruiting around
47,000 women) [28] confirmed the vantage of the HPV
test over pap cytology as a primary screening method.
In this study, HPV 16/18 genotyping with cytology triage
(comparator 2) provides better clinical impacts, while low-
ering the costs. Therefore, it is the most cost-effective CxCa
screening strategy in the Portuguese context. Comparator 2
also reduces annual CxCa incidence and mortality and
Table 3 Test performance inputs of cytology and Cobas® HPV
test (pooled and 16/18 genotyping)
Input Value Source
Cytology (threshold ASCUS)
Sensitivity CIN2 52.6% Castle et al. (2011) [28]
Sensitivity CIN3 52.8% Castle et al. (2011) [28]
Sensitivity CxCa 52.8% assumed to be equivalent to CIN3
Specificity CIN2+ 76.1% Castle et al. (2011) [28]
Cytology (threshold LSIL)
Sensitivity CIN2 39.2% Castle et al. (2011) [28]
Sensitivity CIN3 40.1% Castle et al. (2011) [28]
Sensitivity CxCa 40.1% assumed to be equivalent to CIN3
Specificity CIN2 86.5% Castle et al. (2011) [28]
Cytology (threshold HSIL)
Sensitivity CIN2 20.3% Castle et al. (2011) [28]
Sensitivity CIN3 26.2% Castle et al. (2011) [28]
Sensitivity CxCa 26.2% assumed to be equivalent to CIN3
Specificity CIN2 98.3% Castle et al. (2011) [28]
Cobas® HPV test (pooled)
Sensitivity CIN2 88.2% Castle et al. (2011) [28]
Sensitivity CIN3 92.0% Castle et al. (2011) [28]
Sensitivity CxCa 92.0% assumed to be equivalent to CIN3
Specificity CIN2 57.8% Castle et al. (2011) [28]
Cobas® HPV test with genotyping 16/18
Sensitivity 16/18 CIN2 51.8% Castle et al. (2011) [28]
Sensitivity 16/18 CIN3 59.5% Castle et al. (2011) [28]
Sensitivity 16/18 CxCa 65.3% Castle et al. (2011) [28]
Specificity CIN2 75.3% Castle et al. (2011) [28]
Table 4 Medical costs used in the model
Parameter Euro References
SCREENING COSTS
Office visit (routine/repeat
screening)
31.00€ [29]
Cytology test (liquid-
based)
27.40€ [29]
HPV test (pooled) 27.40€ Assumed to have the same
price as for cytology test
HPV test with 16/18
genotyping
27.40€ Assumed to have the same
price as for cytology test
DIAGNOSTIC COSTS
Office visit (diagnostic
follow-up)
31.00€ [29]
Colposcopy plus biopsy 34.40€ [29]
TREATMENT COSTS
Treatment for cervical
intraepithelial neoplasia
(Grade≥ 2)
907.57€ Adapted from: Costa C [30];
Santana R et al. [31]
Treatment for invasive
cervical cancer
10423.29
€
Adapted from: Costa C [30];
Santana R et al. [31]
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reduces the total annual screening costs in 24.0%, as well as
the cost of detecting a CIN2+ in 19,2%. The screening per-
formance of HPV (pooled) test with cytology triage (com-
parator 1) is lower when compared to comparator 2 in its
detection rates but has similar costs. The improved clinical
outcomes obtained through this HECON modelling result
from an improved screening performance of both HPV
strategies and an earlier detection of CIN2–3 and CxCa.
On the other hand, the substantial cost savings are caused
by the increased length of the routine screening intervals,
allowed by the enhanced sensitivity and negative predictive
value of HPV based screening. The performance of Pap cy-
tology is low in the model, but consistent with data from
an international meta-analysis showing a detection rate of
53,0% [47].
Concerning the triage of HPV positive women, the au-
thors of this study acknowledge the fact that pap cy-
tology performance as a triage marker is affected by an
expected increase in sensitivity and a decrease in specifi-
city [48, 49]. This means that the “real-life” sensitivity of
the HPV based algorithms can be higher and specificity
lower, positively impacting clinical results (CIN2+
detection) and increasing costs. To clarify this subject, a
sensitivity analysis compared results from other studies
that also addressed triage strategies for HPV positive
women, such as POBASCAM [32], PavDag [33] and also
from the ATHENA three years follow up results [34].
The conclusion was that the cost difference towards
cytology-based screening remained higher, consolidating
the main findings on the cost savings created by the
change towards HPV test-based screening.
The model also projects a difference in clinical out-
comes between comparator 1 and 2 strategies: 5.9% in
sensitivity for the detection of CxCa. The model results
suggest that if the individual tests are used in a certain
strategy or algorithm then the number of detected cases
may differ. Although such differences were never re-
ported from clinical trials, they can be partially explained
by the fact that in this simulation, in comparator 1 all
hrHPV positive / NILM cases (including HPV16 and 18
positives) are deferred and that 15.0% of these will actu-
ally miss follow-up.
This study has certain limitations. As any modelling
study, the results are influenced by the input parameters
Fig. 3 Performance of the screening strategies during two screening cycles. Detected cervical cancers and CIN2-CIN3 cases
Table 5 Annual cervical cancer incidence and mortality in the screened population (1,764,000 25–65-year-old Portuguese women)
and per 100,000. The number of colposcopies required per detected disease (CIN2–3 and CxCa)
Current practice: Comparator 1: Comparator 2:
Cytology with pooled HPV
triage
Pooled HPV test with reflex
cytology triage
HPV genotyping with reflex
cytology triage
Screened pop. per 100,000 Screened pop. per 100,000 Screened pop. per 100,000
Annual CxCa incidence 194 9.3 143 6.9 109 5.3
Annual CxCa mortality 56 2.7 34 1.6 22 1.1
Colposcopies per disease (CIN2–2, CxCa) detected 10.1 8.2 9.6
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and structure of the model. The performances of LBC
and the HPV test (pooled and 16/18 genotyping) are
based on data from a trial in the United States, not on
Portuguese data. The clinical results are sensitive to
changes in prevalence of HPV, HPV genotypes 16/18,
CIN2 and CIN3. Also, the referral rates to colposcopy
were determined in this model by the prevalence of the
infection by the 14 hrHPV types in the Portuguese epi-
demiological study and these may differ if prevalence
changes, as it is expectable in a vaccinated population.
Another model limitation is that performance data re-
flect the baseline test (test performance among the gen-
eral population) and that the same test in a re-testing
situation among a previously hrHPV+ population may
be different. The authors acknowledge that the model
should allow two test performance inputs - one at base-
line and another for re-test situation among previously
hrHPV+ women. While HPV vaccination programs im-
pact the cost of screening programs as shown in recently
published real world data [50], this model does not take
that in consideration which may be considered also as a
limitation.
The cost results are sensitive to changes in prices of
cytology, HPV test and screening consultation. In the
absence of a DRG reflecting the use of HPV as a screen-
ing test, the price of HPV tests was assumed the same as
the cytology DRG. The future DRG price for an HPV
test may be different. In this case, the authors tried to
simulate the reality for Portugal as much as possible. In
our country, there is no screening program at national
level, and opportunistic and organized programs occur
regionally with different levels of implementation. In the
current setting, DRG prices are currently used as a refer-
ence for pricing both HPV and Cytology and the volume
of tests would not allow for a cost reduction. A sensitive
analysis varying the price of HPV test to either twice or
half of that of cytology, shows that HPV based screening
algorithms would remain cost-saving independently of
the chosen scenario. Furthermore, the cost of screening
can be lower if more suppliers compete in fair tenders.
The guideline based on reproducibility and equivalent
accuracy defined by Arbin et al. [51] is a milestone in
HPV-based cervical cancer screening. There are cur-
rently 8 HPV DNA assays fully matching these criteria,
which can be recommended for HPV-based cervical can-
cer screening using clinician-collected cervical samples,
half of which offer partial, extended or full genotyping.
This means the offer is large and competitive, making
public tenders able to implement either of the Compara-
tor strategies. This is important not just for Portugal, but
also for other countries. The time-horizon of this model-
ling study is limited to two screening cycles. Policymakers
would like to understand to which level CxCa incidence
and mortality decrease, after several screening cycles.
Fig. 4 Total annual costs of the screening strategies. Budget impact in comparison to the current practice. A breakdown of annual costs per
screening diagnostic
Table 6 Clinical performance of triaging all hrHPV+ women with LBC
Study Sensitivity (CIN2+) Specificity (CIN2+) Relative cost of Comparator 1
ATHENA (Castle PE et al., 2011 [28]) 88.2% 57.8% − 24%
POBASCAM (Dijkstra M et al., 2013 [32]) 66% 81.4% −26%
PavDag (Stanczuk GA. et al., 2017 [33]) 68.3% 89.1% − 26%
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Conclusion
The results suggest that the replacement of the current
screening practice based on cytology testing every three
years to HPV primary screening with cytology triage
every five years improves the detection of CIN2–3 and
CxCa, provides better clinical outcomes and creates sub-
stantial cost-savings for the Portuguese healthcare sys-
tem. These cost-savings are mainly generated by
increasing the screening interval. Further triage of HPV
positive women with partial 16/18 genotyping would im-
prove the efficiency of the screening program. Therefore,
the results of this HECON evaluation confirm the Cer-
vical Cancer Screening recommendations of the Portu-
guese Society of Gynaecology [5] and the ongoing
screening algorithm changes in the Portuguese orga-
nized screening programs. The results of this work also
open directions for future research: a) the inputs used
on this model could be refined with real world data
coming from the organized screening programs, b)
evaluation of the economic benefit of using emerging
biomarkers like p16/ki-67 or methylation to further re-
fine the triage of HPV+ women and c) re-model taking
vaccine immunization into consideration.
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